Personalized Breast Cancer Treatment
121 – 130 of 148
                - show: 10
- |
- sort: year (new to old)
        Close
        
            
    
        Embed this list
<iframe src=""
              width=""
              height=""
              allowtransparency="true"
              frameborder="0">
            </iframe>
        - 2017
- 
                        Mark
        Claudin-4 expression is associated with progression free survival in ovarian cancer, but not with chemotherapy response
    
    - Contribution to journal › Article
 
- 
                        Mark
        Tumor tissue protein signatures reflect histological grade of breast cancer
    (2017) In PLoS ONE- Contribution to journal › Article
 
- 
                        Mark
        Androgen receptor expression and breast cancer mortality in a population-based prospective cohort
    
    - Contribution to journal › Article
 
- 
                        Mark
        Abstract P1-07-17: The SCAN-B study: 5-year summary of a large-scale population-based prospective breast cancer translational genomics platform covering a wide geography of Sweden (NCT02306096)
    
    - Contribution to journal › Published meeting abstract
 
- 
                        Mark
        Molecular characterization of circulating tumor cells from patients with metastatic breast cancer reflects evolutionary changes in gene expression under the pressure of systemic therapy
    
    - Contribution to journal › Article
 
- 
                        Mark
        Nationellt Kvalitetsregister för Bröstcancer (NKBC) : Sammanfattning och vägledning till interaktiva rapporter för 2016
    (2017)- Book/Report › Report
 
- 
                        Mark
        AIB1 is a new putative prognostic biomarker in the luminal A and B-like (HER2-negative) classification of invasive lobular carcinoma
    
    - Contribution to conference › Abstract
 
- 
                        Mark
        Quality of up to 35 years old archival breast cancer tissue in paraffin-blocks for estrogen receptor evaluation
    
    - Contribution to journal › Published meeting abstract
 
- 2016
- 
                        Mark
        Two years of adjuvant tamoxifen provides a survival benefit compared with no systemic treatment in premenopausal patients with primary breast cancer : Long-Term follow-up (> 25 years) of the phase III SBII:2pre trial
    
    - Contribution to journal › Article
 
- 2015
- 
                        Mark
        Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival
    
    - Contribution to journal › Article
 
